Department of Ophthalmology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
APMIS. 2011 Jan;119(1):36-43. doi: 10.1111/j.1600-0463.2010.02689.x. Epub 2010 Nov 17.
Primary orbital meningioma is a rare tumor of the anterior visual pathway and constitutes approximately 2% of all orbital tumors and 1-2% of all meningiomas. The differentiation from secondary orbital meningioma of intracranial origin is sometimes difficult on image. As the tumor often leads to visual loss if left untreated and surgical intervention inevitably causes morbidity, the timing and modality of treatment are very important. We carried out the study involving six cases (mean age: 42.7 years, male to female ratio: 1:5) of primary orbital meningioma to further elucidate its behavior. The clinical signs and symptoms, diagnosis, treatment strategies, and follow-up information are recorded for all cases. The most frequent initial symptoms were visual complaints (100%) and proptosis (67%). In five cases, the diagnosis was based on pathologic findings and the tumors were all grade I meningiomas. In one case, however, the diagnosis was based on radiographic and clinical findings, lacking histologic confirmation. Five patients were operated on, four underwent tumor removal, and one received eyeball exenteration. One patient was treated with Novalis radiotherapy. The mean follow-up period was 8.8 years (range from 9 months to 15 years). All patients experienced loss of vision during the course without exception. No recurrent tumor was found in five cases during follow-up. In case 5, whose eyeball was exenterated, developed recurrent meningioma 7 years later. She received radiotherapy but the tumor was out of control. She expired 8 years after eyeball exenteration. The primary orbital meningioma is aggressive in behavior despite its benign histopathologic features. Loss of vision is frequently seen even after treatment. The tumor could be fatal if surgery and radiotherapy fail to control its intracranial extension.
原发性眼眶脑膜瘤是一种罕见的前视觉通路肿瘤,占所有眼眶肿瘤的 2%左右,占所有脑膜瘤的 1-2%。在影像学上,有时很难将其与颅内来源的继发性眼眶脑膜瘤区分开来。由于肿瘤如果不治疗通常会导致视力丧失,而手术干预不可避免地会引起发病率,因此治疗的时机和方式非常重要。我们对 6 例(平均年龄:42.7 岁,男女比例:1:5)原发性眼眶脑膜瘤进行了研究,以进一步阐明其行为。记录了所有病例的临床症状、诊断、治疗策略和随访信息。最常见的首发症状是视力问题(100%)和眼球突出(67%)。在 5 例中,诊断基于病理发现,肿瘤均为 I 级脑膜瘤。然而,在 1 例中,诊断基于影像学和临床发现,缺乏组织学证实。5 例患者接受了手术治疗,4 例接受了肿瘤切除,1 例接受了眼球摘除。1 例患者接受了 Novalis 放疗。平均随访时间为 8.8 年(9 个月至 15 年)。所有患者在病程中无一例外地出现视力丧失。在随访中,5 例患者未发现复发性肿瘤。在 5 号病例中,眼球被摘除,7 年后发展为复发性脑膜瘤。她接受了放疗,但肿瘤失控。眼球摘除 8 年后去世。尽管原发性眼眶脑膜瘤具有良性的组织病理学特征,但行为具有侵袭性。即使经过治疗,视力丧失也很常见。如果手术和放疗不能控制其颅内延伸,肿瘤可能是致命的。